Growth Hormone Axis · Growth Hormone Axis peptide (research)
Tesamorelin
- Drug class
- Growth Hormone Axis peptide (research)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What Tesamorelin is studied for
- Visceral fat reduction (research)
- Body composition (research)
- Lipid profile support (research)
Mechanism of action
Tesamorelin is being studied in the growth hormone axis category. GHRH analog studied for visceral fat reduction and body composition. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is Tesamorelin?
Tesamorelin is a growth hormone axis peptide. GHRH analog studied for visceral fat reduction and body composition.
What is Tesamorelin studied for?
Published research has examined Tesamorelin for visceral fat reduction, body composition, lipid profile support. Human clinical evidence varies by indication.
Is Tesamorelin FDA-approved?
No. Tesamorelin is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is Tesamorelin used in research?
Protocols vary by study. Tesamorelin is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for Tesamorelin is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.